Source: Annual Congress 2003 - Lung cancer: clinical presentation and prognostic factors



Rating:

Share or cite this content

Citations should be made in the following way:
N. Songur, F. Kalkan, N. Hizel, B. Kuru, H. Cakmak (Ankara, Turkey). Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer. Eur Respir J 2003; 22: Suppl. 45, 1652

Member's Comments

No comment yet.

Related content which might interest you: Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003 Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Apelin expression is a prognostic factor in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 Serum angiopoietins as a clinical marker for resected early lung cancer Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008 Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Source: Eur Respir J 2007; 30: 627-632 Year: 2007 Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 C-reactive protein and assessment of chemotherapy response in advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004 Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007 The prognostic significance of sVEGF levels in patients(pts) with Non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005 Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker Source: International Congress 2019 – Biology of lung cancer Year: 2019 Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012 Bcl-2 as a prognostic factor for survival in small-cell lung cancer Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 385s Year: 2006 Procalitonin: A prognosis factor in lung cancer and a marker for small-cell lung cancer Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011 Effects of prognostic factors on survival of the patients of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 326s Year: 2005